eligibility_summary
Eligibility: Adults (≥18) with histologically confirmed solid tumors, able to complete questionnaires, and consenting. Group I: on anti‑PD‑1/PD‑L1/CTLA‑4 or CDK inhibitors for ≥3 months (AIFA‑approved for tumor type). Group II: candidates to start the same AIFA‑approved therapies. Exclude: age <18, pre‑existing skin disease, chronic steroids, psychiatric disorders/antidepressants, or no consent.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT05878964 is an observational study of patients receiving standard anticancer therapies—immune checkpoint inhibitors (ICIs) or CDK4/6 inhibitors—assessing cutaneous adverse events and quality of life. No experimental drugs are given, outcomes are measured via EQ-5D-5L, FACT-G, and FACT-EGFRI-18. Drugs/pathways: • Anti‑PD‑1 monoclonal antibodies (e.g., nivolumab, pembrolizumab): block PD‑1 on activated T cells, preventing PD‑L1/PD‑L2–mediated inhibitory signaling and restoring T‑cell cytotoxicity. • Anti‑PD‑L1 monoclonal antibodies (e.g., atezolizumab, durvalumab, avelumab): bind PD‑L1 on tumor/immune cells, blocking PD‑1 engagement (and sometimes CD80), reactivating T cells. • Anti‑CTLA‑4 monoclonal antibody (e.g., ipilimumab): blocks CTLA‑4 on T cells, enhancing CD28–B7 costimulation during priming, may reduce intratumoral Tregs. • CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib): oral small molecules that inhibit CDK4/6, prevent RB phosphorylation, halt G1→S transition, can increase tumor antigen presentation and T‑cell activity. Targets: PD‑1/PD‑L1 and CTLA‑4 checkpoints on T cells, cyclin D–CDK4/6–RB–E2F cell‑cycle pathway in tumor cells.